LOGIN  |  REGISTER
Terns Pharmaceuticals
Viking Therapeutics

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2023 on Thursday, November 9, 2023

October 05, 2023 | Last Trade: US$71.65 0.89 1.26

MARLBOROUGH, Mass. / Oct 05, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2023 on Thursday, November 9, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Interested participants may listen to the call by dialing (866) 400-0049 (in the United States and Canada) or +1 (773) 305-6867 (for international callers) and referencing access code 1937661. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. A webcast replay will be available approximately two hours after the call ends.

Hologic will provide a live and webcast replay of the call on the Company’s website at investors.hologic.com. The call will be available there for 30 days.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB